Cabaletta Bio (NASDAQ:CABA) Downgraded to “Hold” at Zacks Investment Research

Cabaletta Bio (NASDAQ:CABAGet Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Tuesday, Zacks.com reports.

According to Zacks, “Cabaletta Bio Inc. is a clinical stage biotechnology company. It is focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company’s product pipeline consists of DSG3-CAART, DSG3/1-CAART, MuSK-CAART and FVIII-CAART which are in clinical stage. Cabaletta Bio Inc. is based in Philadelphia, United States. “

Other equities analysts have also recently issued reports about the company. HC Wainwright reissued a “buy” rating and issued a $11.00 price target on shares of Cabaletta Bio in a report on Monday, May 16th. Mizuho lowered their price objective on Cabaletta Bio from $22.00 to $20.00 and set a “buy” rating for the company in a research report on Friday, March 18th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, Cabaletta Bio currently has an average rating of “Buy” and a consensus target price of $15.50.

CABA stock traded down $0.05 during midday trading on Tuesday, hitting $1.28. 182,090 shares of the stock were exchanged, compared to its average volume of 168,191. The stock’s 50-day moving average price is $1.71 and its 200-day moving average price is $4.19. The stock has a market cap of $37.09 million, a price-to-earnings ratio of -0.70 and a beta of 1.53. Cabaletta Bio has a fifty-two week low of $1.17 and a fifty-two week high of $14.95.

Cabaletta Bio (NASDAQ:CABAGet Rating) last released its quarterly earnings results on Thursday, May 12th. The company reported ($0.45) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.08. Analysts predict that Cabaletta Bio will post -2.07 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently modified their holdings of CABA. Samlyn Capital LLC lifted its stake in shares of Cabaletta Bio by 295.8% during the fourth quarter. Samlyn Capital LLC now owns 1,383,381 shares of the company’s stock worth $5,243,000 after purchasing an additional 1,033,906 shares in the last quarter. Point72 Asset Management L.P. acquired a new position in shares of Cabaletta Bio during the third quarter worth about $10,944,000. Renaissance Technologies LLC acquired a new position in shares of Cabaletta Bio in the first quarter worth about $405,000. BlackRock Inc. lifted its stake in shares of Cabaletta Bio by 52.6% in the fourth quarter. BlackRock Inc. now owns 504,190 shares of the company’s stock worth $1,910,000 after acquiring an additional 173,709 shares in the last quarter. Finally, Acadian Asset Management LLC acquired a new position in shares of Cabaletta Bio in the first quarter worth about $298,000. Institutional investors own 62.75% of the company’s stock.

Cabaletta Bio Company Profile (Get Rating)

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells.

Read More

Get a free copy of the Zacks research report on Cabaletta Bio (CABA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Cabaletta Bio (NASDAQ:CABA)

Receive News & Ratings for Cabaletta Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cabaletta Bio and related companies with MarketBeat.com's FREE daily email newsletter.